Biopolym. Cell. 2001; 17(2):152-159.
Molecular Mechanisms of Differentiation
Potential tumour suppressor role of TSC-22 gene in human brain tumours
1Shostak K. O., 1Dmitrenko V. V., 1Garifulin O. M., 2Rozumenko V. D., 2Khomenko O. V., 2Zozulya Yu. A., 3Zehetner G., 1Kavsan V. M.
  1. Institute of Molecular Biology and Genetics, NAS of Ukraine
    150, Akademika Zabolotnoho Str., Kyiv, Ukraine, 03680
  2. Institute of Neurosurgery named after A. P. Romodanov, NAMS of Ukraine
    32, Manuilskogo Str., Kyiv, Ukraine, 04050
  3. Max Planck Institute for Molecular Genetics
    Ihnestrasse 63-73, 14195 Berlin, Germany


At present some biological mechanisms assumed to initiate and promote astrocytoma formation have been partly revealed. Several putative genes in regions strongly suggested to harbour tumour suppressors should be identified. For example, these are the regions on the chromosomal arms 1p, 10p, 13q, 19g and 22g. More comprehensive approach in the analysis of astrocytomas includes gene expression determination in order to focus not only on the structural alterations but on the regulatory differences as well. Such changes in gene expression are important determinants of normal cellular physiology and, if disturbed, directly contribute to abnormal cellular physiology, including cancer. The search of new genes, the activation or inactivation of which is associated with the progression of astrocytic tumours, is still a goal of intensive investigations. In this work, more than a hundred cDNA clones differed in hybridization signals between human normal brain and glioblastoma multiform have been found by screening of high density grids of arrayed human fetal brain and human postnatal brain cDNA libraries. The repeated differential hybridization of the clones selected by primary screening, as well as the analysis of RNA from human adult normal brain and glial tumour samples have revealed 16 nucleotide sequences, which content had changed in tumours. The decreased content in astrocytic tumours has been determined for TSC-22 mRNA corresponding to cDNA in ICRFp507J 1041 clone from the library of human fetal brain cDNAs. The Northern blot hybridization of RNA from different human brain tumours has shown very low amount of TSC-22 mRNA in a bulk of the investigated samples of glioblastoma multiform, anaptastic astrocytoma, WHO grade II astrocytoma and some other tumours. The expression of TSC-22 gene has not been detected at all in astrocytoma WHO grade 11 as well as in meningioma, brain sarcoma, sarcomatous meningioma and oligodendroglioma (one sample of each tumor kind). The Southern blot hybridization has revealed the deletions in genomic loci of TSC-22 gene in two of three anaplastic astrocytomas analyzed. A significantly decreased level of the production of TSC-22 mRNA in the human brain tumours and, as it was shown previously, in the salivary gland tumours, an antiproliferative role of TSC-22 protein, the localization of TSC-22 gene in 13q14 region close to the known tumour suppressor retinoblastoma (Rb) gene, and the deletions in this genomic locus strongly evidence TSC-22 to be a tumour suppressor.


[1] Maier D, Zhang Z, Taylor E, Hamou MF, Gratzl O, Van Meir EG, Scott RJ, Merlo A. Somatic deletion mapping on chromosome 10 and sequence analysis of PTEN/MMAC1 point to the 10q25-26 region as the primary target in low-grade and high-grade gliomas. Oncogene. 1998;16(25):3331-5.
[2] Rosenberg JE, Lisle DK, Burwick JA, Ueki K, von Deimling A, Mohrenweiser HW, Louis DN. Refined deletion mapping of the chromosome 19q glioma tumor suppressor gene to the D19S412-STD interval. Oncogene. 1996;13(11):2483-5.
[3] Ino Y, Silver JS, Blazejewski L, Nishikawa R, Matsutani M, von Deimling A, Louis DN. Common regions of deletion on chromosome 22q12.3-q13.1 and 22q13.2 in human astrocytomas appear related to malignancy grade. J Neuropathol Exp Neurol. 1999;58(8):881-5.
[4] Simons A, Jeuken JW, Eleveld MJ, Boerman RH, Geurts Van Kessel A. Isolation and characterization of glioblastoma-associated homozygously deleted DNA fragments from chromosomal region 9p21 suggests involvement of multiple tumour suppressor genes. J Pathol. 1999;189(3):402-9.
[5] Smith JS, Tachibana I, Allen C, Chiappa SA, Lee HK, McIver B, Jenkins RB, Raffel C. Cloning of a human ortholog (RPH3AL) of (RNO)Rph3al from a candidate 17p13.3 medulloblastoma tumor suppressor locus. Genomics. 1999;59(1):97-101.
[6] Farrell WE, Clayton RN. Tumour suppressor genes in pituitary tumour formation. Baillieres Best Pract Res Clin Endocrinol Metab. 1999;13(3):381-93.
[7] Bello MJ, de Campos JM, Vaquero J, Kusak ME, Sarasa JL, Rey JA. High-resolution analysis of chromosome arm 1p alterations in meningioma. Cancer Genet Cytogenet. 2000;120(1):30-6.
[8] Shibanuma M, Kuroki T, Nose K. Isolation of a gene encoding a putative leucine zipper structure that is induced by transforming growth factor beta 1 and other growth factors. J Biol Chem. 1992;267(15):10219-24.
[9] Kester HA, Blanchetot C, den Hertog J, van der Saag PT, van der Burg B. Transforming growth factor-beta-stimulated clone-22 is a member of a family of leucine zipper proteins that can homo- and heterodimerize and has transcriptional repressor activity. J Biol Chem. 1999;274(39):27439-47.
[10] Kawamata H, Nakashiro K, Uchida D, Hino S, Omotehara F, Yoshida H, Sato M. Induction of TSC-22 by treatment with a new anti-cancer drug, vesnarinone, in a human salivary gland cancer cell. Br J Cancer. 1998;77(1):71-8.
[11] Nakashiro K, Kawamata H, Hino S, Uchida D, Miwa Y, Hamano H, Omotehara F, Yoshida H, Sato M. Down-regulation of TSC-22 (transforming growth factor beta-stimulated clone 22) markedly enhances the growth of a human salivary gland cancer cell line in vitro and in vivo. Cancer Res. 1998;58(3):549-55.
[12] Dmitrenko VV, Garifulin OM, Smikodub AI, Kavsan VM. An analysis of human genome expression by using libraries of the cDNA from different organs. Tsitol Genet. 1995;29(2):64-71.
[13] Dmitrenko VV, Garifulin OM, Shostak EA, Smikodub AI, Kavsan VM. The characteristics of different types of mRNA expressed in the human brain. Tsitol Genet. 1996;30(5):41-7.
[14] Dmitrenko VV, Shostak KO, Garifulin OM, Zozulya YA, Kavsan VM. Changes of gene expression in human astrocytic brain tumors. Eksp Onkol. 1998; 20(3-4):191-7
[15] Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci U S A. 1977;74(12):5463-7.
[16] Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987;162(1):156-9.
[17] Sambrook J, Fritch EF, Maniatis T. Molecular cloning. A laboratory manual. New York: Cold Spring Harbor Lab. press, 1989.
[18] Diatchenko L, Lau YF, Campbell AP, Chenchik A, Moqadam F, Huang B, Lukyanov S, Lukyanov K, Gurskaya N, Sverdlov ED, Siebert PD. Suppression subtractive hybridization: a method for generating differentially regulated or tissue-specific cDNA probes and libraries. Proc Natl Acad Sci U S A. 1996;93(12):6025-30.
[19] Nguyen C, Rocha D, Granjeaud S, Baldit M, Bernard K, Naquet P, Jordan BR. Differential gene expression in the murine thymus assayed by quantitative hybridization of arrayed cDNA clones. Genomics. 1995;29(1):207-16.
[20] Jay P, Ji JW, Marsollier C, Taviaux S, Berg?-Lefranc JL, Berta P. Cloning of the human homologue of the TGF beta-stimulated clone 22 gene. Biochem Biophys Res Commun. 1996;222(3):821-6.
[21] Ohta S, Shimekake Y, Nagata K. Molecular cloning and characterization of a transcription factor for the C-type natriuretic peptide gene promoter. Eur J Biochem. 1996;242(3):460-6.
[22] Dmitrenko VV, Kavsan VM. Variability of polyadenylation sites in mRNAs from human fetal liver. FEBS Lett. 1991;280(2):284-6.
[23] Simonsen CC, Levinson AD. Analysis of processing and polyadenylation signals of the hepatitis B virus surface antigen gene by using simian virus 40-hepatitis B virus chimeric plasmids. Mol Cell Biol. 1983;3(12):2250-8.
[24] Sasavage NL, Smith M, Gillam S, Woychik RP, Rottman FM. Variation in the polyadenylylation site of bovine prolactin mRNA. Proc Natl Acad Sci U S A. 1982;79(2):223-7.
[25] Wiedemann LM, Perry RP. Characterization of the expressed gene and several processed pseudogenes for the mouse ribosomal protein L30 gene family. Mol Cell Biol. 1984;4(11):2518-28.
[26] Aho S, Tate V, Boedtker H. Multiple 3' ends of the chicken pro alpha 2(I) collagen gene. Nucleic Acids Res. 1983;11(16):5443-50.
[27] Hern?ndez-Lucas C, Royo J, Paz-Ares J, Ponz F, Garc?a-Olmedo F, Carbonero P. Polyadenylation site heterogeneity in mRNA encoding the precursor of the barley toxin ?-hordothionin. FEBS Lett. 1986;200(1):103–6.
[28] Hamil KG, Hall SH. Cloning of rat Sertoli cell follicle-stimulating hormone primary response complementary deoxyribonucleic acid: regulation of TSC-22 gene expression. Endocrinology. 1994;134(3):1205-12.
[29] Sawada K, Agata K, Eguchi G. Characterization of terminally differentiated cell state by categorizing cDNA clones derived from chicken lens fibers. Int J Dev Biol. 1996;40(3):531-5.
[30] Sillard R, Schulz-Knappe P, Vogel P, Raida M, Bensch KW, Forssmann WG, Mutt V. A novel 77-residue peptide from porcine brain contains a leucine-zipper motif and is recognized by an antiserum to delta-sleep-inducing peptide. Eur J Biochem. 1993;216(2):429-36.
[31] Treisman JE, Lai ZC, Rubin GM. Shortsighted acts in the decapentaplegic pathway in Drosophila eye development and has homology to a mouse TGF-beta-responsive gene. Development. 1995;121(9):2835-45.
[32] Riechmann V, van Cr?chten I, Sablitzky F. The expression pattern of Id4, a novel dominant negative helix-loop-helix protein, is distinct from Id1, Id2 and Id3. Nucleic Acids Res. 1994;22(5):749-55.
[33] Kester HA, van der Leede BM, van der Saag PT, van der Burg B. Novel progesterone target genes identified by an improved differential display technique suggest that progestin-induced growth inhibition of breast cancer cells coincides with enhancement of differentiation. J Biol Chem. 1997;272(26):16637-43.
[34] Ohta S, Yanagihara K, Nagata K. Mechanism of apoptotic cell death of human gastric carcinoma cells mediated by transforming growth factor beta. Biochem J. 1997;324 ( Pt 3):777-82.
[35] Henson JW, Schnitker BL, Correa KM, von Deimling A, Fassbender F, Xu HJ, Benedict WF, Yandell DW, Louis DN. The retinoblastoma gene is involved in malignant progression of astrocytomas. Ann Neurol. 1994;36(5):714-21.
[36] Huhn SL, Mohapatra G, Bollen A, Lamborn K, Prados MD, Feuerstein BG. Chromosomal abnormalities in glioblastoma multiforme by comparative genomic hybridization: correlation with radiation treatment outcome. Clin Cancer Res. 1999;5(6):1435-43.
[37] Venkatraj VS, Begemann M, Sobrino A, Bruce JN, Weinstein IB, Warburton D. Genomic changes in glioblastoma cell lines detected by comparative genomic hybridization. J Neurooncol. 1998;36(2):141-8.
[38] Harada K, Nishizaki T, Ozaki S, Kubota H, Ito H, Sasaki K. Intratumoral cytogenetic heterogeneity detected by comparative genomic hybridization and laser scanning cytometry in human gliomas. Cancer Res. 1998;58(20):4694-700.
[39] Uchida D, Kawamata H, Omotehara F, Miwa Y, Hino S, Begum NM, Yoshida H, Sato M. Over-expression of TSC-22 (TGF-beta stimulated clone-22) markedly enhances 5-fluorouracil-induced apoptosis in a human salivary gland cancer cell line. Lab Invest. 2000;80(6):955-63.
[40] Omotehara F, Uchida D, Hino S, Begum NM, Yoshida H, Sato M, Kawamata H. In vivo enhancement of chemosensitivity of human salivary gland cancer cells by overexpression of TGF-beta stimulated clone-22. Oncol Rep. 2000;7(4):737-40.